journal
MENU ▼
Read by QxMD icon Read
search

International Clinical Psychopharmacology

journal
https://www.readbyqxmd.com/read/29112517/use-of-antidementia-drugs-in-german-patients-with-alzheimer-s-disease
#1
Philipp Hessmann, Richard Dodel, Erika Baum, Matthias J Müller, Greta Paschke, Bernhard Kis, Jan Zeidler, Mike Klora, Jens-Peter Reese, Monika Balzer-Geldsetzer
The objective of this study was to evaluate the use of antidementia drugs (ADDs) in patients with Alzheimer's disease (AD) regarding German guideline recommendations and to assess correlations between the use of ADDs and the patients' characteristics. A total of 395 community-dwelling and institutionalized patients with AD across all severity stages of dementia were recruited in this cross-sectional study. Associations between the prescription of ADDs and patients' sociodemographic and clinical parameters (neuropsychiatric symptoms, cognitive capacity, daily activities, and health-related quality of life) were analyzed in multiple logistic regression analyses...
November 6, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29112001/a-phase-ii-study-to-evaluate-the-pharmacokinetics-safety-and-tolerability-of-risperidone-ism-multiple-intramuscular-injections-once-every-4-weeks-in-patients-with-schizophrenia
#2
Lourdes A Carabias, Jordi Llaudó, Ignacio Ayani, Javier Martínez, Robert E Litman, Ibón Gutierro
This study characterized the pharmacokinetics, safety, and tolerability of Risperidone ISM, a new long-acting intramuscular formulation, for monthly administration without oral supplementation. Patients with schizophrenia received multiple intramuscular injections of 75 mg in the gluteal or deltoid muscle at 28-day intervals. Of the 70 randomized patients, 67 received at least one dose of study medication. The mean Cmax of the active moiety was achieved 24-48 h (tmax) after each administration, regardless of injection site...
November 3, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29084087/salsalate-as-an-adjunctive-treatment-for-psychopathology-and-cognition-in-patients-with-schizophrenia-a-pilot-study
#3
Yanli Luo, Fang Liu, Radhika Natarajan, Nawras Shukair, Paul Copeland, Xiaoduo Fan
This pilot study examined the effect of adjunctive salsalate on psychopathology and cognition in patients with schizophrenia. This was a 12-week, open-label trial of salsalate (1.5 g, twice per day) in patients with schizophrenia. Psychopathology, cognition, and daily function were assessed at baseline and week 12 using various rating scales. Blood levels of inflammatory markers including white blood cell count, high-sensitivity C-reactive protein, and interleukin-6 levels were also measured. Eight patients completed the study...
October 27, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29068794/results-from-a-drug-utilization-study-of-extended-release-quetiapine-fumarate-prescribed-by-psychiatrists-as-treatment-for-major-depressive-disorder-in-selected-countries-in-the-european-union
#4
Robert S Brody, Charles L Liss, Heather Wray, Kari Kastango, Allison Bryant, Alban Fabre, Anneli Thuresson
This multicenter, observational drug utilization (DU) study (NCT01594996) investigated the profile of patients and specialist providers who prescribed extended release quetiapine fumarate (quetiapine XR) for treatment of major depressive disorder (MDD) across five European countries (Germany, Italy, Romania, Spain, and Sweden). A DU data abstraction form captured information on the characteristics of physicians, patients, and drugs utilized in the medical management of depressive episodes in MDD, where the therapeutic regimen included quetiapine XR...
October 24, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29064911/efficacy-of-antidepressants-over-placebo-is-similar-in-two-armed-versus-three-armed-or-more-armed-randomized-placebo-controlled-trials
#5
Yusuke Ogawa, Toshi A Furukawa, Nozomi Takeshima, Yu Hayasaka, Lauren Z Atkinson, Shiro Tanaka, Andrea Cipriani, Georgia Salanti
Previous studies have reported that effect sizes of antidepressants were larger in two-armed than in three-armed or more-armed (multiarmed) randomized trials, where the probability of being allocated to placebo is lower. However, these studies have not taken into account the publication bias, differences among antidepressants, or covariance in multiarmed studies, or examined sponsorship bias. We searched published and unpublished randomized-controlled trials that compared placebo with 21 antidepressants for the acute treatment of major depression in adults...
October 23, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29064910/a-molecular-pathway-analysis-informs-the-genetic-risk-for-arrhythmias-during-antipsychotic-treatment
#6
Ellen Kure Fischer, Antonio Drago
Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of the present investigation. The aim of this study was to identify a molecular pathway enriched in single nucleotide polymorphisms associated with antipsychotic-induced QTc modifications. In total, 661 schizophrenic individuals from the CATIE study, M=486 (73...
October 23, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29064909/pexacerfont-as-a-crf1-antagonist-for-the-treatment-of-withdrawal-symptoms-in-men-with-heroin-methamphetamine-dependence-a-randomized-double-blind-placebo-controlled-clinical-trial
#7
Mohammad-Javad Morabbi, Emran Razaghi, Ehsan Moazen-Zadeh, Hamideh Safiaghdam, Mohamad R Zarrindast, Nasim Vousoghi, Shahin Akhondzadeh
We assessed the efficacy of pexacerfont, a CRF1 antagonist, for the treatment of withdrawal symptoms. In this randomized, double-blind, placebo-controlled clinical trial, male patients with amphetamine or opioid dependence, on the basis of the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR), in the age range 18-55 years, received either pexacerfont or placebo (300, 200, and 100 mg/day in the first, second, and third week, respectively). No antidepressants, behavioral interventions, or substitution therapy were administered...
October 23, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29035904/improvement-in-cognitive-abilities-following-cabergoline-treatment-in-patients-with-a-prolactin-secreting-pituitary-adenoma
#8
Itziar Montalvo, Marta Llorens, Laia Caparrós, Montserrat Pamias, Jordi Torralbas, Olga Giménez-Palop, Assumpta Caixàs, Diego J Palao, Javier Labad
Hyperprolactinaemia may affect sexual and reproductive functioning. However, recent studies suggest that increased prolactin levels may also have negative effects on cognition. We aimed to study whether the reduction in prolactin levels by cabergoline in patients with hyperprolactinaemia is followed by an improvement in cognitive tasks. We studied seven patients with hyperprolactinaemia caused by a prolactinoma that had an indication to start treatment with cabergoline. All patients were assessed twice (baseline and 6-12 months after cabergoline treatment) with a cognitive battery...
October 13, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28938233/no-apparent-association-between-bipolar-disorder-and-cancer-in-a-large-epidemiological-study-of-outpatients-in-a-managed-care-population
#9
Natan R Kahan, Barbara Silverman, Irena Liphshitz, Dan-Andrei Waitman, Itzhak Ben-Zion, Alexander M Ponizovsky, Abraham Weizman, Alexander Grinshpoon
An association between bipolar disorder (BD) and cancer risk has been reported. The purpose of this study was to investigate this association through linkage analysis of a national HMO database and a national cancer registry. All members of the Leumit Health Services (LHS) HMO of Israel from 2000 to 2012 were included. Members with a recorded diagnosis of BD and a record of at least one written or dispensed prescription for pharmacotherapy for treatment of BD were classified as patients with BD. We linked the LHS population with the Israel National Cancer Registry database to capture all cases of cancer reported...
September 21, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28906325/antidepressant-combination-versus-antidepressants-plus-second-generation-antipsychotic-augmentation-in-treatment-resistant-unipolar-depression
#10
Gabriella Gobbi, Maykel F Ghabrash, Nicolas Nuñez, John Tabaka, Jessica Di Sante, Marie Saint-Laurent, Stephen Vida, Theodore Kolivakis, Nancy Low, Pablo Cervantes, Linda Booij, Stefano Comai
Patients with treatment-resistant unipolar depression (TRD) are treated with antidepressant combinations (ADs) or with second-generation antipsychotics plus AD (SGA+AD) augmentation; however, the clinical characteristics, the factors associated independently with response to SGA+AD, and the outcome trajectories have not yet been characterized. We performed a naturalistic study on the latest stable trial (medication unchanged for about 3 months) in 86 TRD patients with resistance to at least two ADs trials, who received ADs (n=36) or SGA+AD (n=50) treatments...
September 12, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28806194/paliperidone-palmitate-3-month-treatment-results-in-symptomatic-remission-in-patients-with-schizophrenia-a-randomized-multicenter-double-blind-and-noninferiority-study
#11
Adam J Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, David Hough, Maju Mathews
The current analysis assessed symptomatic and functional remission achieved following paliperidone palmitate 3-month (PP3M) versus 1-month (PP1M) treatment in patients (age: 18-70 years) with schizophrenia, previously stabilized on PP1M. Following a less than or equal to 3-week screening, and a 17-week, flexible-dosed, open-label phase [PP1M: day 1 (150 mg eq. deltoid), day 8 (100 mg eq. deltoid), weeks 5, 9, and 13 (50, 75, 100, or 150 mg eq., deltoid/gluteal)], clinically-stable patients were randomized (1 : 1) to PP3M (fixed-dose, 175, 263, 350, or 525 mg eq...
November 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28763344/the-impact-of-fatigue-and-energy-on-work-functioning-and-impairment-in-patients-with-major-depressive-disorder-treated-with-desvenlafaxine
#12
David Sarfati, Vanessa C Evans, Edwin M Tam, Cindy Woo, Grant L Iverson, Lakshmi N Yatham, Raymond W Lam
Fatigue and low energy are cardinal symptoms of major depressive disorder (MDD) that have an impact on work functioning. Antidepressants with noradrenergic activity have been hypothesized to improve symptoms of fatigue and low energy. We examined the impact of these symptoms on work functioning in patients with MDD treated with the serotonin and noradrenaline reuptake inhibitor, desvenlafaxine. A secondary analysis was carried out from a study of employed adult outpatients (n=35) with MDD and subjective cognitive complaints treated with desvenlafaxine 50-100 mg/day for 8 weeks...
November 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28727644/cariprazine-specificity-profile-in-the-treatment-of-acute-schizophrenia-a-meta-analysis-and-meta-regression-of-randomized-controlled-trials
#13
Filippo Corponi, Alessandro Serretti, Stuart Montgomery, Chiara Fabbri
Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic. Meta-analytic evidence of efficacy in acute schizophrenia and specific groups of patients is lacking. We carried out a meta-analysis in patients with acute schizophrenia to evaluate the efficacy of cariprazine over placebo and active comparators in overall symptoms, positive and negative symptoms and quality of life. Low and high (≥6 mg/day) doses were tested separately. The possible effect of clinical-demographic modulators was also tested...
November 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28704228/patient-attitudes-to-clozapine-initiation
#14
Siobhan H Gee, Sukhwinder S Shergill, David M Taylor
Clozapine is widely underused. No study has assessed views of patients suitable for, but not yet receiving, clozapine. We aimed to assess views of clozapine in patients eligible for clozapine but not yet prescribed it by conducting semistructured interviews with acutely unwell hospital in-patients. We interviewed 61 of 116 eligible patients and 50 (82%) answered all questions. At interview, 33 (54%) of 61 participants had heard of clozapine and 17 (30%) of 57 participants said they would take it if asked. Overall, 31 (57%) of 54 respondents said blood testing would not preclude them taking clozapine...
November 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28692485/safety-and-tolerability-of-cariprazine-in-patients-with-acute-exacerbation-of-schizophrenia-a-pooled-analysis-of-four-phase-ii-iii-randomized-double-blind-placebo-controlled-studies
#15
Willie Earley, Suresh Durgam, Kaifeng Lu, István Laszlovszky, Marc Debelle, John M Kane
Cariprazine, a potent dopamine D3 and D2 receptor partial agonist antipsychotic with preferential binding to D3 receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from the four acute trials in the cariprazine schizophrenia clinical development program (NCT00404573; NCT00694707; NCT01104766; NCT01104779) was carried out using the overall safety population (all patients who received ≥1 dose of study drug) and modal daily dose subgroups (1...
November 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28657934/multitarget-botanical-pharmacotherapy-in-major-depression-a-toxic-brain-hypothesis
#16
Siu W Tang, Wayne H Tang, Brain E Leonard
A significant number of patients with major depression do not respond optimally to current antidepressant drugs. As depression is likely to be a heterogeneous disorder, it is possible that existing neurotransmitter-based antidepressant drugs do not fully address other pathologies that may exist in certain cases. Biological pathologies related to depression that have been proposed and studied extensively include inflammation and immunology, hypercortisolemia, oxidative stress, and impaired angiogenesis. Such pathologies may induce neurodegeneration, which in turn causes cognitive impairment, a symptom increasingly being recognized in depression...
November 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28628502/placebo-response-in-trichotillomania
#17
Jon E Grant, Samuel R Chamberlain, Sarah A Redden, Brian L Odlaug, Michael van Ameringen, Darin D Dougherty, Nancy J Keuthen, Suck W Kim
Trichotillomania is a functionally impairing, often overlooked disorder with no Food and Drug Administration-approved medications indicated for its treatment. The ability of clinical trials to detect the beneficial effects of pharmacologic treatment in trichotillomania has been hampered by the high placebo response rate. Very little is known about baseline demographic and clinical characteristics that may be predictive of placebo response in such patients. Overall, 104 participants assigned to placebo were pooled from five double-blind trials conducted at three sites in the USA and Canada...
November 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28617681/psychotropic-drugs-prescription-in-undocumented-migrants-and-indigent-natives-in-italy
#18
Cesare Cerri, Gianfrancesco Fiorini, Silvia Bini, Antonello E Rigamonti, Nicoletta Marazzi, Alessandro Sartorio, Silvano G Cella
To evaluate psychotropic drug use in undocumented migrants and natives in the same conditions of poverty. We studied drug dispensation by a nongovernmental organization during the year 2014. Drugs were identified according to the Anatomical Chemical Therapeutic classification and their quantity was measured in defined daily doses (DDD). We determined the percentage of patients taking at least one medicine with psychotropic activity in relation to the total number of patients receiving medicines of any class...
September 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28598899/long-term-function-and-psychosocial-outcomes-with-venlafaxine-extended-release-75-225%C3%A2-mg-day-versus-placebo-in-the-prevent-study
#19
Koichiro Watanabe, Michael E Thase, Toshiaki Kikuchi, Takashi Tsuboi, Yuko Asami, Elizabeth Pappadopulos, Min Zhang, Matthieu Boucher, Susan Kornstein
This post-hoc analysis evaluated long-term psychosocial outcomes in patients with recurrent major depressive disorder treated with venlafaxine extended release (ER) 75-225 mg/day or placebo. Patients who responded to 10-week venlafaxine ER 75-300 mg/day treatment and maintained response through a 6-month continuation treatment were assigned randomly to venlafaxine ER or placebo maintenance-phase treatment. Data from responders to acute and continuation venlafaxine ER 75-225 mg/day treatment were analyzed during 12-month maintenance treatment while receiving venlafaxine ER of up to 225 mg/day...
September 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28542035/trends-and-factors-associated-with-antipsychotic-use-among-elderly-patients-with-dementia-in-taiwan-from-2005-to-2013-a-population-based-study
#20
Yu-Wen Chiu, Chih-Wan Huang, Pei-Jung Chen, Nan-Wen Yu, Hui-Ju Tsai, Chi-Shin Wu, Chia-Ming Chang
This study aimed to examine the trends and factors associated with antipsychotic prescriptions for elderly outpatients with dementia in Taiwan from 2005 to 2013. We assessed the annual prescription patterns of antipsychotic medications among elderly patients attending outpatient visits for dementia between 2005 and 2013 using the National Health Insurance Research Database in Taiwan. We also carried out logistic regression analyses to test the trends and associated factors. We found that any antipsychotic prescriptions for elderly patients making visits for dementia increased slightly, from 25...
September 2017: International Clinical Psychopharmacology
journal
journal
29324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"